dc.contributor.author | Tedim, Ana P. | |
dc.contributor.author | Rodriguez, Irene | |
dc.contributor.author | Aktas, Zerrin | |
dc.contributor.author | Canton, Rafael | |
dc.contributor.author | Diez-Aguilar, Maria | |
dc.contributor.author | Isabel Morosini, Maria | |
dc.date.accessioned | 2021-03-03T18:47:59Z | |
dc.date.available | 2021-03-03T18:47:59Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | Diez-Aguilar M., Isabel Morosini M., Tedim A. P. , Rodriguez I., Aktas Z., Canton R., "Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, cilt.59, sa.10, ss.6039-6045, 2015 | |
dc.identifier.issn | 0066-4804 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_51185d09-cd68-4da1-aad8-102dd404781d | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/57686 | |
dc.identifier.uri | https://doi.org/10.1128/aac.00822-15 | |
dc.description.abstract | The antibacterial activity of fosfomycin-tobramycin combination was studied by time-kill assay in eight Pseudomonas aeruginosa clinical isolates belonging to the fosfomycin wild-type population (MIC = 64 mu g/ml) but with different tobramycin susceptibilities (MIC range, 1 to 64 mu g/ml). The mutant prevention concentration (MPC) and mutant selection window (MSW) were determined in five of these strains (tobramycin MIC range, 1 to 64 mu g/ml) in aerobic and anaerobic conditions simulating environments that are present in biofilm-mediated infections. Fosfomycin-tobramycin was synergistic and bactericidal for the isolates with mutations in the mexZ repressor gene, with a tobramycin MIC of 4 mu g/ml. This effect was not observed in strains displaying tobramycin MICs of 1 to 2 mu g/ml due to the strong bactericidal effect of tobramycin alone. Fosfomycin presented higher MPC values (range, 2,048 to > 2,048 mu g/ml) in aerobic and anaerobic conditions than did tobramycin (range, 16 to 256 mu g/ml). Interestingly, the association rendered narrow or even null MSWs in the two conditions. However, for isolates with high-level tobramycin resistance that harbored aminoglycoside nucleotidyltransferases, time-kill assays showed no synergy, with wide MSWs in the two environments. glpT gene mutations responsible for fosfomycin resistance in P. aeruginosa were determined in fosfomycin-susceptible wild-type strains and mutant derivatives recovered from MPC studies. All mutant derivatives had changes in the GlpT amino acid sequence, which resulted in a truncated permease responsible for fosfomycin resistance. These results suggest that fosfomycin-tobramycin can be an alternative for infections due to P. aeruginosa since it has demonstrated synergistic and bactericidal activity in susceptible isolates and those with low-level tobramycin resistance. It also prevents the emergence of resistant mutants in either aerobic or anaerobic environments. | |
dc.language.iso | eng | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Mikrobiyoloji | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | FARMAKOLOJİ VE ECZACILIK | |
dc.subject | Farmakoloji ve Toksikoloji | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Eczacılık | |
dc.subject | Temel Eczacılık Bilimleri | |
dc.subject | Temel Bilimler | |
dc.title | Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations | |
dc.type | Makale | |
dc.relation.journal | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | |
dc.contributor.department | Hospital Universitario Ramon y Cajal , , | |
dc.identifier.volume | 59 | |
dc.identifier.issue | 10 | |
dc.identifier.startpage | 6039 | |
dc.identifier.endpage | 6045 | |
dc.contributor.firstauthorID | 225240 | |